JBF Capital’s Aldeyra Therapeutics ALDX Stock Holding History

JBF Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-20,000	Closed	-$276K	–	86
2018 Q3	$276K	Buy	+20,000	New	+$162K	0.04%	58

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

JBF Capital's ALDX Position: Q4 2018 in Review

JBF Capital sold out of Aldeyra Therapeutics (ALDX) in Q4 2018, closing a stake of 20,000 shares — an estimated $276K sold.

JBF Capital first reported a position in ALDX in Q3 2018 and held it in 1 quarter. The position peaked at $276K in Q3 2018. 77 funds tracked by Wall St. Rank hold ALDX as of Q4 2018.

JBF Capital reported no remaining Aldeyra Therapeutics position as of Q4 2018 after selling out during the quarter.
JBF Capital sold 20,000 Aldeyra Therapeutics shares in Q4 2018, an estimated $276K.
JBF Capital first reported a position in Aldeyra Therapeutics in Q3 2018 and held it in 1 quarter.
JBF Capital's Aldeyra Therapeutics position peaked at $276K in Q3 2018.
77 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2018.

Based on JBF Capital's 13F filing for Q4 2018, filed 12 Feb 2019.